Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ketoconazole

(Synonyms: Xolegel, R-41400, Extina, (±)-Ketoconazol) Copy Product Info
😃Good

Synonyms: Xolegel, R-41400, Extina, (±)-Ketoconazol

Catalog No. T0679 Copy Product Info
Purity: 99.95%
😃Good
Ketoconazole (R-41400) is an imidazole antifungal agent with broad-spectrum antifungal activity that primarily acts by inhibiting the biosynthesis of ergosterol in the fungal cell membrane. Ketoconazole inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol. This leads to damage to the cell membrane structure and permeability, consequently inhibiting fungal growth and producing an antifungal effect. In addition, ketoconazole is a non-selective cytochrome P450 (CYP) inhibitor, specifically inhibiting drug-metabolizing enzymes such as human CYP3A4. In terms of endocrinology, ketoconazole also inhibits various enzymes involved in steroid synthesis (CYP17A1, CYP11A1).
Pack SizePriceUSA StockGlobal StockQuantity
50 mg$31In StockIn Stock
100 mg$44In StockIn Stock
500 mg$68In StockIn Stock
1 g$89In StockIn Stock
1 mL x 10 mM (in DMSO)$48In StockIn Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.95%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Ketoconazole (R-41400) is an imidazole antifungal agent with broad-spectrum antifungal activity that primarily acts by inhibiting the biosynthesis of ergosterol in the fungal cell membrane. Ketoconazole inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol. This leads to damage to the cell membrane structure and permeability, consequently inhibiting fungal growth and producing an antifungal effect. In addition, ketoconazole is a non-selective cytochrome P450 (CYP) inhibitor, specifically inhibiting drug-metabolizing enzymes such as human CYP3A4. In terms of endocrinology, ketoconazole also inhibits various enzymes involved in steroid synthesis (CYP17A1, CYP11A1).
Targets & IC50
Cyclosporine oxidase:0.19 mM, Testosterone 6β-hydroxylase:0.22 mM
In vitro
Methods: Human liver microsomes were incubated at 37°C with ketoconazole (0.3, 1, 2, 3, 5, 10 μM) and CYP3A-specific substrates testosterone and midazolam. High-performance liquid chromatography (HPLC) was used to quantify the formation of metabolites (6β-hydroxy testosterone and 1'-hydroxy midazolam).
Results: Ketoconazole inhibited CYP3A activity in a dose-dependent manner at all concentrations tested, reducing activity to below 3% (for testosterone) at 10 μM. [1]
Methods: U87 glioma cells and patient-derived glioblastoma stem cells (GSCs) were treated with ketoconazole at concentrations ranging from 0.1 to 100 μM for 48–72 hours. Cell proliferation and apoptosis were assessed via Annexin V/PI staining.
Results: Ketoconazole treatment reduced cell proliferation and increased apoptosis rates. [2]
In vivo
Methods: U87-luc cells or patient-derived GSC were implanted in situ into the brains of immunodeficient mice. After tumor formation, mice were randomly assigned to treatment groups. Daily intraperitoneal injections of Ketoconazole (50 mg/kg) or solvent control were administered for 4 consecutive weeks. Tumor growth was monitored via bioluminescence imaging, and mouse survival was recorded.
Results: Tumor growth was significantly suppressed in the ketoconazole group, with markedly prolonged mouse survival. Histological analysis revealed reduced tumor cell proliferation, increased apoptosis, and decreased metabolic activity within tumors. [2]
Methods: Wild-type mice received intraperitoneal injections of ketoconazole (50 mg/kg), followed approximately 30 minutes later by intravenous administration of a radiolabeled tracer ([¹¹C]lopipridil or [¹¹C]dLop). Mice were euthanized 30 minutes after tracer injection, and blood and whole brain samples were collected.
Results: Ketoconazole (50 mg/kg, i.p.) partially inhibited the N-demethylation of [¹¹C]lopipridil in vivo, elevated its plasma concentration, and reduced the entry of polar metabolites into the brain. [3]
SynonymsXolegel, R-41400, Extina, (±)-Ketoconazol
Kinase Assay
Whole Cell [3H]R1881 Binding Assay: Fibroblasts are grown to confluence in five or six 150 cm2 tissue culture flasks for routine assay. This usually requires 4-6 weeks from the time of the initial seeding of the cell line. All studies are performed between passages 3-20. Two days before assay, the medium is changed to one lacking fetal calf serum. This is repeated again 24 hours before assay. Competition assays are performed with 0.5-1.0 nM [3H]R1881 and increasing amounts of the nonradioactive compounds. Binding to low affinity sites is determined in the presence of 5 × 10-7 M R1881 and is subtracted from whole cell binding of [3H]R 1881 obtained in the absence of any inhibitor to assess binding to 5 high affinity site
Cell Research
HT29-S-B6 cells (5×105) are plated in 35-mm Petri dishes. The next day, the medium is changed and effectors are added in a small volume (10-20 μL). The incubation medium is renewed every day during the experiments. The same triplicate dishes are used for cell counts, [3H]thymidine incorporation, and flow cytometry. [3H]Thymidine (0.5 μCi) is allowed to incorporate for 24 hours; at the end of incubation, cells are rinsed with 1 mL of medium, detached with 1 mL of trypsin-EDTA, and diluted (1:3) with the culture medium. An aliquot (0.5-1 mL) is used for cell count with a Coulter Counter.(Only for Reference)
Chemical Properties
Molecular Weight531.43
FormulaC26H28Cl2N4O4
Cas No.65277-42-1
SmilesC([C@]1(O[C@@H](COC2=CC=C(C=C2)N3CCN(C(C)=O)CC3)CO1)C4=C(Cl)C=C(Cl)C=C4)N5C=CN=C5
Relative Density.1.4046 g/cm3 (Estimated)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 25 mg/mL (47.04 mM), Sonication and heating are recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.53 mg/mL (1 mM), Solution.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8817 mL9.4086 mL18.8172 mL94.0858 mL
5 mM0.3763 mL1.8817 mL3.7634 mL18.8172 mL
10 mM0.1882 mL0.9409 mL1.8817 mL9.4086 mL
20 mM0.0941 mL0.4704 mL0.9409 mL4.7043 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Keywords

Related Tags: Ketoconazole chemical structure | Ketoconazole in vivo | Ketoconazole in vitro | Ketoconazole formula | Ketoconazole molecular weight